These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 29275953)

  • 21. Genome Editing for Cystic Fibrosis.
    Wang G
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intestinal organoids for Cystic Fibrosis research.
    de Poel E; Lefferts JW; Beekman JM
    J Cyst Fibros; 2020 Mar; 19 Suppl 1():S60-S64. PubMed ID: 31787574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies.
    Fanen P; Wohlhuter-Haddad A; Hinzpeter A
    Int J Biochem Cell Biol; 2014 Jul; 52():94-102. PubMed ID: 24631642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Theratyping in cystic fibrosis.
    Crawford KJ; Downey DG
    Curr Opin Pulm Med; 2018 Nov; 24(6):612-617. PubMed ID: 30124524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cellular heterogeneity of CFTR expression and function in the lung: implications for gene therapy of cystic fibrosis.
    Jiang Q; Engelhardt JF
    Eur J Hum Genet; 1998 Jan; 6(1):12-31. PubMed ID: 9781011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients.
    Amaral MD
    J Intern Med; 2015 Feb; 277(2):155-166. PubMed ID: 25266997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cystic fibrosis - an example of personalized and precision medicine.
    Skov M; Hansen CR; Pressler T
    APMIS; 2019 May; 127(5):352-360. PubMed ID: 30761610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. rAAV-CFTRΔR Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and Cystic Fibrosis Mice.
    Vidović D; Carlon MS; da Cunha MF; Dekkers JF; Hollenhorst MI; Bijvelds MJ; Ramalho AS; Van den Haute C; Ferrante M; Baekelandt V; Janssens HM; De Boeck K; Sermet-Gaudelus I; de Jonge HR; Gijsbers R; Beekman JM; Edelman A; Debyser Z
    Am J Respir Crit Care Med; 2016 Feb; 193(3):288-98. PubMed ID: 26509335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
    Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
    Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetics of Cystic Fibrosis: Clinical Implications.
    Egan ME
    Clin Chest Med; 2016 Mar; 37(1):9-16. PubMed ID: 26857764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene therapy in cystic fibrosis.
    Prickett M; Jain M
    Transl Res; 2013 Apr; 161(4):255-64. PubMed ID: 23273902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cystic fibrosis transmembrane conductance regulator modulators: the end of the beginning.
    Barry PJ; Ronan N; Plant BJ
    Semin Respir Crit Care Med; 2015 Apr; 36(2):287-98. PubMed ID: 25826594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repairing the basic defect in cystic fibrosis - one approach is not enough.
    Farinha CM; Matos P
    FEBS J; 2016 Jan; 283(2):246-64. PubMed ID: 26416076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fundamental and translational research in Cystic Fibrosis - why we still need it.
    Farinha CM; Brodsky JL; Pedemonte N
    J Cyst Fibros; 2023 Mar; 22 Suppl 1():S1-S4. PubMed ID: 36577595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New approaches to genetic therapies for cystic fibrosis.
    Christopher Boyd A; Guo S; Huang L; Kerem B; Oren YS; Walker AJ; Hart SL
    J Cyst Fibros; 2020 Mar; 19 Suppl 1():S54-S59. PubMed ID: 31948871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies.
    Rubenstein RC
    Mol Diagn Ther; 2006; 10(5):293-301. PubMed ID: 17022692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vector-specific complementation profiles of two independent primary defects in cystic fibrosis airways.
    Zhang Y; Jiang Q; Dudus L; Yankaskas JR; Engelhardt JF
    Hum Gene Ther; 1998 Mar; 9(5):635-48. PubMed ID: 9551612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutic advances in cystic fibrosis in 2014].
    Durupt S; Mazur S; Reix P
    Rev Pneumol Clin; 2016 Feb; 72(1):77-86. PubMed ID: 25727661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.